Leica Biosystems Bond Oracle HER2 IHC System - Manual (Página 27)

Página 27 de 28
Español
Leica Biosystems Bond Oracle HER2 IHC System Instructions for Use TA9145 ES-CE-Rev_E 18/06/2013
Español
Referencias
1. Corbett IP, Henry JA, Angus B et al. NCL-CB11, A new monoclonal antibody recognizing the internal
domain of the c-erbB-2 oncogene protein effective for use on formalin-fixed, paraffin-embedded
tissue. Journal of Pathology. 1990; 161:15-25.
2. Lonardo F, Di Marco E, King CR, Pierce JH, Segatto O, Aaronson SA, et al. The normal
erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence
of ligand. New Biologist 1990; 2: 992-1003.
3. Carter P, Presta L, Gorman CM, Ridgway JBB, Henner D, Wong WLT, et al. Humanization of an
anti-p185HER2 antibody for human cancer therapy. Proceedings of the National Academy of Science
USA 1992; 89: 4285-9.
4. Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A. p185HER2 monoclonal
antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor
necrosis factor. Molecular & Cell Biology 1989; 9: 1165-72.
5. Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, et al. Differential responses of human
tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunology and Immunotherapy
1993; 37: 255-63.
6. Baselga J, Norton L, Albanell J, Kim Y-M, Mendelsohn J. Recombinant humanized anti-HER2
antibody (Herceptin ® ) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/
neu overexpressing human breast cancer xenografts. Cancer Research 1998; 58: 2825-31.
7. Nakane PK and Pierce GB. Enzyme labeled antibodies: Preparations and applications for the
localization of antigens. Journal of Histochemistry and Cytochemistry. 1967; 14: 929-931.
8. Tsutsumi Y, Serizawa A and Kawai K. Enhanced polymer one-step staining (EPOS) for proliferating
cell nuclear antigen and Ki-67 antigen-applications to intraoperative frozen diagnosis. Pathology
International . 1995; 45(2): 108-115.
9. Walker RA, Bartlett JMS Dowsett M, Ellis IO, Hanby AN, Jasani B, Miller K and Pinder SE. HER2
Testing in the UK- Further Update To Recommendations. Journal of Clinical Pathology 2008
10. Dickson, RB and Lippman, ME. Genes, Oncogenes, and Hormones. Boston, Kluwer Academic Publishers,
1992.
11. Keatings, L. et al. c-erbB-2 oncoprotein expression in mammary and extramammary Paget’s
disease: an immunohistochemical study. Histopathology. 1990; 17: 234-247.
12. The National Committee for Clinical Laboratory Standards (NCCLS). Quality assurance for
immunocytochemistry; Approved guideline. NCCLS document MM4-A (1-56238-396-5) NCCLS, 940
West Valley Road, Suite 1400, Wayne, Pennsylvania 1999; 19087-1898: USA
13. Elias JM, Gown AM, Nakamura RM, Wilbur DC, Herman GE, Jaffe ES, et al. Special Report:
Quality control in immunohistochemistry. American Journal of Clinical Pathology 1989 ;92: 836-43.
14. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER2/neu proto-oncogene in normal
human adult and fetal tissues. Oncogene 1990; 5: 953-62.
15. Nadji, M. and Morales, A. R. Immunoperoxidase, part I: the techniques and its pitfalls. Laboratory
Medicine 1983; 14: 767.
16. Jackson P. 2007. Quality Assurance in Immunohistochemistry. In: Immunohistochemistry, 2007
(ed. Renshaw S), PP 205-237. Scion Publishing Ltd.
17. Omata M, Liew C-T, Ashcavai M, Peters RL. Nonimmunologic binding of horseradish peroxidase to
hepatitis B surface antigen: a possible source of error in immunohistochemistry. American Journal of
Clinical Pathology 1980; 73: 626-32.
18. Bartlet JMS, Ibrahim M, et al External Quality Assurance of HER2 FISH Testing: Results of a UK
NEQAS Pilot Scheme. Journal of Clinical Pathology. 2006.
Correcciones a la publicación anterior
Branding, códigos de productos adicionales, el estudio de reproducibilidad.
Fecha de emisión
18 de junio de 2013